Perspective's Cancer Therapy Candidate Receives FDA Fast Track Designation; Shares Rise Pre-Bell
MT newswire2026/10/08 10:5306:53 AM EDT, 10/08/2026 (MT Newswires) -- Perspective Therapeutics (CATX) said Thursday that the US Food and Drug Administration, or FDA, granted fast track designation for the development of PSV359, an experimental cancer treatment for adults with advanced tumors that cannot be removed through surgery or have spread to other parts of the body. The investigational therapy is being studied in an ongoing Phase 1/2a trial in patients with advanced fibroblast activation protein-positive solid tumors, the company said. The company said early human imaging data showed strong tumor uptake and rapid kidney clearance for PSV359. The FDA's fast track program is aimed at accelerating the development and review of therapies for serious conditions with unmet medical needs, the company added. Shares rose around 4.9% in premarket trading.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Canaccord Genuity: Lowers Oklo's target price to $66
"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.
Dental treatment company vVardis has announced the terms for its $214 million US IPO.
Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss
Novo Nordisk reports that some patients treated with Wegovy have shown improvements in liver conditions.
Crypto prices
More
